Cyclo Therapeutics Inc. (CTDH)
Stock Price:
$0.120 USD
0.000 (0.00%)
Updated Aug 14, 2020 4:00 PM EDT - End of day
Key Info
| Market Cap |
17.00M |
| Revenue (ttm) |
1.11M |
| Net Income (ttm) |
-8.26M |
| Shares Out |
141.67M |
| EPS (ttm) |
-0.07 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 14, 2020 |
| Last Price |
$0.120 |
| Previous Close |
$0.120 |
| Change ($) |
0.000 |
| Change (%) |
0.00% |
| Day's Open |
0.127 |
| Day's Range |
0.116 - 0.135 |
| Day's Volume |
26,139 |
| 52-Week Range |
0.080 - 0.440 |
More Stats
| Market Cap |
17.00M |
| Enterprise Value |
16.04M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
141.67M |
| Float |
74.32M |
| EPS (basic) |
-0.06 |
| EPS (diluted) |
-0.07 |
| FCF / Share |
-0.06 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
n/a |
| Short Ratio |
n/a |
| Short % of Float |
n/a |
| Beta |
-0.47 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
15.29 |
| PB Ratio |
6.62 |
| Revenue |
1.11M |
| Operating Income |
-8.28M |
| Net Income |
-8.26M |
| Free Cash Flow |
-7.22M |
| Net Cash |
955,802 |
| Net Cash / Share |
0.01 |
| Gross Margin |
69.21% |
| Operating Margin |
-744.43% |
| Profit Margin |
-742.90% |
| FCF Margin |
-649.59% |
| ROA |
-246.91% |
| ROE |
-338.60% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
1.25
Current: $0.120
High
1.25
Target: 1.25
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 1.01 | 1.01 | 1.24 | 1.50 | 0.95 | 1.57 | 1.69 | 1.04 | 1.03 | 0.80 |
| Revenue Growth | -0.42% | -18.28% | -17.64% | 58.13% | -39.36% | -7.43% | 62.05% | 1.27% | 28.6% | - |
| Gross Profit | 0.93 | 0.91 | 1.10 | 1.30 | 0.83 | 1.29 | 1.27 | 0.91 | 0.76 | 0.69 |
| Operating Income | -7.54 | -4.27 | -3.84 | -4.21 | -2.41 | -0.56 | 0.34 | 0.16 | -0.07 | -0.01 |
| Net Income | -7.53 | -4.26 | -3.83 | -4.22 | -2.55 | -0.59 | 0.20 | 0.07 | -0.10 | -0.04 |
| Shares Outstanding | 108 | 81.76 | 72.04 | 63.35 | 56.21 | 50.54 | 37.17 | 36.68 | 35.81 | 33.71 |
| Earnings Per Share | -0.07 | -0.05 | -0.05 | -0.07 | -0.05 | -0.01 | 0.01 | 0.01 | -0.01 | -0.01 |
| EPS Growth | - | - | - | - | - | - | 0% | - | - | - |
| Operating Cash Flow | -6.59 | -3.19 | -3.06 | -2.95 | -1.99 | -0.63 | 0.56 | 0.06 | 0.19 | 0.21 |
| Capital Expenditures | - | - | - | 0.92 | -0.42 | -0.17 | -0.15 | -0.17 | -0.55 | -0.44 |
| Free Cash Flow | -6.59 | -3.19 | -3.06 | -2.04 | -2.41 | -0.81 | 0.40 | -0.11 | -0.37 | -0.23 |
| Cash & Equivalents | 2.82 | 2.25 | 1.31 | 0.99 | 1.84 | 2.38 | 0.27 | 0.02 | 0.13 | 0.11 |
| Total Debt | 0.02 | - | - | - | 0.74 | 0.79 | 0.85 | 0.99 | 0.84 | 0.44 |
| Net Cash / Debt | 2.81 | 2.25 | 1.31 | 0.99 | 1.10 | 1.59 | -0.58 | -0.96 | -0.71 | -0.33 |
| Assets | 4.11 | 2.92 | 2.09 | 1.87 | 4.74 | 5.29 | 2.79 | 2.62 | 2.79 | 1.93 |
| Liabilities | 3.18 | 1.93 | 0.94 | 0.34 | 1.00 | 0.92 | 0.99 | 1.07 | 1.37 | 0.53 |
| Book Value | 0.94 | 0.99 | 1.15 | 1.53 | 3.75 | 4.37 | 1.80 | 1.55 | 1.42 | 1.40 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Cyclo Therapeutics Inc. |
| Country |
United States |
| Employees |
5 |
| CEO |
Nathan Scott Fine |
Stock Information
| Ticker Symbol |
CTDH |
| Stock Exchange |
US OTC |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
OTCMKTS: CTDH |
Description
Cyclo Therapeutics, Inc., a biotechnology company, develops cyclodextrin-based products for the treatment of diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug for the treatment of Niemann-Pick Type C disease. The company also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. It has a collaboration with the Chattanooga Center for Neurologic Research. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in October 2019. Cyclo Therapeutics, Inc. was founded in 1990 and is based in Gainesville, Florida.